A group of scientists has tested a new drug for the prevention of episodic migraine, which is 4 to 14 migraine days per month. Results showed that the new drug called erenumab could cut the number of attacks in half.
The results of the six-month Phase III STRIVE study were published on the New England Journal of Medicine. Intended to examine the effectiveness of erenumab would as a preventive treatment for episodic migraine, the study was presented at the 69th Annual Meeting of the American Academy of Neurology.
With 955 patients enrolled, the study was led by Dr. Peter Goadsby, Professor of Neurology at King’s College London. Administered subcutaneously at a dose of 70 mg or 140 mg per month over a period of 6 months, erenumab significantly reduced migraine frequency, its effects on daily activities and the use of acute migraine–specific medication.
“The results of STRIVE represent a real transition for migraine patients from poorly understood, repurposed treatments, to a specific migraine-designed therapy,” Goadsby said in a statement included in the announcement released by Novartis. He added that as with the monoclonal antibody developments in general, the study represents “an incredibly important step forward for migraine understanding and migraine treatment.”
Developed by Amgen Inc., erenumab is the first and only fully human monoclonal antibody of its kind, designed to specifically block the calcitonin gene-related peptide (CGRP) receptor. Treatments that target the CGRP pathway could be provided in the future to migraine sufferers who neither respond to nor tolerate the current therapies, according to Goadsby.
Meanwhile, here is a clip about home remedies for migraine relief: